Company Focus
Chiesi Farmaceutici
Latest Chiesi Farmaceutici News
Pharmaceutical
Privately-held Italian drugmaker Chiesi today announced UK Medicines and Healthcare products Regulatory Agency (MHRA) approval of Clenil Modulite (beclometasone; 100mcg and 200mcg) formulated with a next-generation, non-PFAS, low GWP propellant. 21 July 2026
Related News
Insights
Company Spotlight
Latest News & Features of interest to Chiesi Farmaceutici
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted Teva Pharmaceutical Industries' New Drug Application (NDA) for ecopipam and granted it priority review. 19 August 2026
Biotechnology
US biotech BioMarin Pharmaceutical today announced that it has entered into a definitive agreement to acquire Dutch biotech firm Alesta Therapeutics to gain Alesta's lead clinical-stage asset, ALE1. 18 August 2026
Pharmaceutical
US pharma major Bristol Myers Squibb was hit with adverse developments on two separate legal fronts this month, both stemming from its 2019 acquisition of Celgene and its cardiovascular franchise. 17 August 2026
Biosimilars
Swiss affordable medicines company Sandoz today announced a major development, manufacturing and commercialization collaboration agreement with Shanghai Henlius Biotech, marking another significant step to broaden patient access to high-quality biosimilar medicines worldwide. 17 August 2026
Biotechnology
US biotech firm Capricor Therapeutics has won a reprieve for its Duchenne muscular dystrophy (DMD) cell therapy deramiocel, telling investors the FDA is prepared to consider an amended filing built around upper-limb muscle function rather than the cardiac claim rejected by an advisory panel last month. 17 August 2026
Pharmaceutical
Deal-making news last week including Spanish dermatology specialist Almirall entering into a research collaboration with China’s CrystalO Biopharma. Sentynl entered a deal to license lung disease candidate alvelestat from Mereo BioPharma, which could earn the latter nearly half a billion dollars. Also, PTC Therapeutics is acquiring Fabry disease candidate ST-920 from Sangamo competitive bankruptcy auction. On the M&A front, Jazz Pharmaceuticals announced an $820 million upfront bid to acquire Actio Biosciences and its investigational epilepsy treatment ABS-1230. 16 August 2026
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Romvimza (vimseltinib) to treat adult patients with enosynovial giant cell tumor (TGCT) when it impacts movement or where surgery is not an option. 14 August 2026
Biotechnology
Danish biotech Zealand Pharma has sold almost all of its remaining economic interests in the polycythemia vera candidate rusfertide to royalty investor Royalty Pharma for $100 million, turning a legacy entitlement it no longer treats as core into cash ahead of a US regulatory decision due within weeks. 14 August 2026
Biotechnology
A new survey reveals that US biotechnology companies focused on developing treatments for rare and serious diseases overwhelmingly prefer to conduct first-in-human (FIH) clinical trials in the USA. 13 August 2026
Biotechnology
USA-based rare disease drug developer PTC Therapeutics announced that it was selected as the winning bidder to acquire ST-920 – a biologics license application (BLA)-stage one-time administered AAV gene therapy for Fabry disease – from Sangamo Therapeutics in a competitive bankruptcy auction. 13 August 2026
Latest In Brief for Chiesi Farmaceutici
Pharmaceutical
A consortium led by CVC Capital Partners has launched a 10.9 billion euros ($12.65 billion) bid to take Italian drugmaker Recordati (RECI: MI) private, in a deal that would tighten the buyout specialist’s control of the company and extend its bet on the rare disease market. 23 May 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze